{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:18:46Z","timestamp":1787811526230,"version":"build-2784847793"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Agonistic anti-CD40 antibodies and related CD40 agonist biologics are being developed across multiple solid tumors using diverse biologic formats, delivery routes, and combination regimens. Safety is central to their clinical development but remains difficult to interpret because high-grade adverse events in combination settings may reflect partner therapies, and safety outcomes are reported inconsistently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and evidence map of the clinical safety of CD40 agonists in patients with solid tumors. Major bibliographic databases, trial registries, and conference sources were searched. Reports from the same trial population were linked to avoid double counting. Safety-reporting availability was prespecified as a primary output, and exploratory proportional synthesis was performed only when patient-level event counts and denominators were clearly reported or could be reproducibly derived. Clinical activity and immunological or pharmacodynamic findings were summarized descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven independent peer-reviewed primary safety reports covering 12 agents or biologics were included. The evidence base was uneven and concentrated in conventional systemically administered monoclonal antibodies, basket or mixed-tumor populations, pancreatic cancer, and melanoma. Fc-engineered, tumor-targeted or bispecific, non-monoclonal-antibody, and intratumoral or locally delivered approaches were each represented by few reports, precluding comparison by format or route. Patient-level safety counts and denominators were inconsistently reported, and cytokine-release grading frameworks varied or were unspecified. Several clinically important outcomes were therefore suitable for mapping but not pooling. Four exploratory pools were interpreted as hypothesis-generating: any-grade treatment-related adverse events were consistently frequent but had limited value for distinguishing clinically important toxicity, whereas high-grade and treatment-related estimates were imprecise. In combination studies, pooled estimates reflected regimen-level toxicity rather than toxicity attributable specifically to CD40 agonism. Clinical activity and immunological or pharmacodynamic findings were widely reported but too heterogeneous for formal comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review provides a structured map of where CD40 agonist safety evidence is available and where important gaps remain. Current evidence does not support definitive comparison of toxicity across biologic formats, delivery routes, or treatment regimens. More consistent patient-level reporting, with explicit denominators, treatment attribution, and grading frameworks, is needed to enable future comparative safety assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261414658.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1908586","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:39:35Z","timestamp":1787809175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Agonistic anti-CD40 antibodies in patients with solid tumors: a systematic review and evidence map of clinical safety, with exploratory proportional synthesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinrui","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Du","sequence":"additional","affiliation":[{"name":"Department of VIP Dental Service, Peking University Stomatological Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","article-title":"CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies","volume":"19","author":"Bullock","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393451","article-title":"Dendritic cell subsets and implications for cancer immunotherapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"21","author":"Enell Smith","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2357714","article-title":"Next-generation CD40 agonists for cancer immunotherapy","volume":"24","author":"Andersson","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940674","article-title":"Next generation CD40 agonistic antibodies for cancer immunotherapy","volume":"13","author":"Salomon","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.2507","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005584","article-title":"Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas","volume":"11","author":"Coveler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","article-title":"A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors","volume":"41","author":"Moreno","year":"2023","journal-title":"Invest New Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"356","author":"Lineberry","year":"2017","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"Anz J Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013613","article-title":"Phase I\/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)","volume":"14","author":"Ninmer","year":"2026","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"R\u00fcter","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Annals of Oncology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor","year":"2018","journal-title":"OncoImmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001153","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients","volume":"8","author":"Machiels","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"International Journal of Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10609","DOI":"10.1038\/s41467-025-66092-1","article-title":"REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer","volume":"16","author":"Kucukcelebi","year":"2025","journal-title":"Nature Communications"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","article-title":"A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1\/PD-L1","volume":"27","author":"Weiss","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"B37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.ccr-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/2767-9764.CRC-24-0513","article-title":"A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers","volume":"5","author":"Ko","year":"2025","journal-title":"Cancer Research Communications"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1551","article-title":"Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: a phase I\/II study","author":"Bentebibel","year":"2026","journal-title":"Cancer Discovery"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01157-8","article-title":"Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial","volume":"7","author":"Melero","year":"2026","journal-title":"Nat Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/1750743X.2024.2359359","article-title":"A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors","volume":"16","author":"Tran","year":"2024","journal-title":"Immunotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s43018-026-01150-1","article-title":"Tumor-localized CD40 agonism with MP0317, a FAP \u00d7 CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study","volume":"7","author":"Steeghs","year":"2026","journal-title":"Nature Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41416-026-03430-0","article-title":"Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"134","author":"Drew","year":"2026","journal-title":"British Journal of Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective fc\u03b3R engagement","volume":"29","author":"Dahan","year":"2016","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2326-6066.cir-13-0152","article-title":"Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer","volume":"2","author":"Richman","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1147467","article-title":"Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives","volume":"14","author":"Dadas","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:39:37Z","timestamp":1787809177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1908586"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1908586","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1908586"}}